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Recombinant expression of proteins of interest in Escherichia coli is an
important tool in the determination of protein structure. However, lack of
expression and insolubility remain signiﬁcant challenges to the expression and
crystallization of these proteins. The SSGCID program uses a wheat germ cell-
free expression system as a rescue pathway for proteins that are either not
expressed or insoluble when produced in E. coli. Testing indicates that the
system is a valuable tool for these protein targets. Further increases in solubility
were obtained by the addition of the NVoy polymer reagent to the reaction
mixture. These data indicate that this eukaryotic cell-free expression system has
a high success rate and that the addition of speciﬁc reagents can increase the
yield of soluble protein.
1. Introduction
1.1. Protein expression
An impediment to the successful production of large quantities of
natively folded proteins in Escherichia coli is the tendency of many
proteins to become insoluble when overexpressed. In order to
successfully produce quantities of these proteins sufﬁcient for crys-
tallization, additional methods are necessary; in vitro systems using
other organisms as well as cell-free systems utilizing extracts from
prokaryotic or eukaryotic organisms have been developed (Gra ¨slund
et al., 2008; Endo & Sawasaki, 2006). Eukaryotic systems utilize a
protein-folding apparatus that has evolved to direct the folding of
more complex proteins, while cell-free systems are not dependent on
the survival of a cell (Klammt et al., 2006).
Prokaryotic cell-free systems exist, although these systems have
demonstrated limited improvement over prokaryotic in vivo
methods; the misfolding of proteins remains a signiﬁcant problem
(Hillebrecht & Chong, 2008). The wheat germ cell-free expression
system combines the advantages of cell-free and eukaryotic systems
and is well suited for expression of difﬁcult-to-express proteins such
as disulﬁde-bond-containing or integral membrane proteins (Endo &
Sawasaki, 2006; Kawasaki et al., 2003; Spirin, 2004; Vinarov, Loushin
Newman & Markley, 2006; Vinarov, Loushin Newman, Tyler et al.,
2006; Klammt et al., 2006; Tyler et al., 2005). This system has been
used as a rescue pathway for human proteins that are not soluble in
both in vivo and in vitro E. coli systems (Langlais et al., 2007).
A recent analysis of in vivo and in vitro expression of Arabidopsis
thaliana proteins found that 95–97% of a set of protein targets were
soluble when expressed via a wheat germ cell-free system in com-
parison to 40% when expressed using the E. coli cell-based system
(Langlais et al., 2007). These two systems were also tested on a
Plasmodium falciparum protein set and while detectable protein was
obtained for 30% of the proteins in E. coli, protein was obtained for
75% when expressed in the eukaryotic cell-free system (Tyler et al.,
2005). Thus, eukaryotic in vitro systems, speciﬁcally the wheat germ
cell-free system, hold signiﬁcant promise.
1.2. Solubility
There is extensive literature on the variables leading to insoluble
recombinant expression of proteins. Protein aggregation remains asigniﬁcant problem in E. coli expression systems. Tags used to purify
proteins often affect the solubility, and the addition of various tags
can lead to the soluble expression of a previously insoluble protein
(Gordon et al., 2008; Ohana et al., 2009; Sun et al., 2011). Modiﬁcation
of the sequence, such as the addition of highly acidic sequences, can
also solubilize a previously insoluble protein (Zhang et al., 2004) and
different tags may affect solubility (Widakowich et al., 2011). Proteins
with similar features in their native sequences may have a greater
tendency towards solubility when recombinantly expressed in vivo.
The frequency of individual amino acids as well as the frequency of
different types of amino acids within a protein has been shown to
affect in vivo solubility in E. coli. It is likely that secondary structure
also plays a role in protein solubility and the tendency to form
amyloid bodies in vivo (Idicula-Thomas & Balaji, 2005, 2007). If the
protein produced in E. coli is primarily insoluble, denaturing and
refolding can be attempted. Common denaturing reagents include
guanidinium and urea. The refolding process can be aided by the
addition of stabilizing agents such as l-arginine (Kudou et al., 2011).
Cell-free systems have an additional advantage in the production of
soluble protein, as agents that aid in protein folding can be directly
added to the translation reaction. Eukaryotic expression systems,
including the wheat germ cell-free system, have been demonstrated
to raise the solubility of a protein (Dadashipour et al., 2011; Klammt
et al., 2006; Langlais et al., 2007).
2. Materials and methods
2.1. Protein selection
Proteins in this analysis are a subset of protein targets entered into
the Seattle Structural Genomics Center for Infectious Disease
(SSGCID) pipeline. The target organisms were NIAID category A–C
pathogens. Proteins within target organisms were selected bioinfor-
matically for homology to current drug targets or nominated for
structure determination by the scientiﬁc community. Proteins were
eliminated if they contained more than eight cysteines or a predicted
transmembrane domain in the absence of a signal peptide. A total of
44 proteins were used in this analysis, a summary of which can be
laboratory communications
1028 Guild et al.  Wheat germ cell-free expression system Acta Cryst. (2011). F67, 1027–1031
Table 1
Protein set used in this analysis.
Solubility in E. coli reﬂects testing; ND, no data. Expression and solubililty ratings reﬂect small-scale expression using WEPRO1240H. Expression key: , less than 15 mg ml
1; +, less
than 0.30 mg ml
1; ++, less than 0.75 mg ml
1 but greater than 0.30 mg ml
1; +++ greater than 0.75 mg ml
1 Solubility key: , no soluble protein; +, less than 25% total protein soluble; ++,
25–75% total protein soluble; +++, greater than 75% total protein soluble.
Species Accession ID
Sequence
cloned Annotation
Solubility in
E. coli in vivo
Cell-free
expression
Cell-free
solubility
Anaplasma marginale ACR67103.1 Full length Major surface protein 2 variant 9H1 ND + 
Anaplasma marginale ACR67104.1 Full length Major surface protein 2 ND 
Anaplasma marginale ACR67105.1 Full length Major surface protein 2 variant E6F7/1/2 ND + 
Bartonella henselae YP_033889.1 Full length UDP-3-O-(3-hydroxymyristoyl) N-acetylglucosamine deacetylase Insoluble +++ ND
Bartonella henselae YP_032889.1 Full length ABC transporter/ATP-binding protein Insoluble ++ ++
Bartonella henselae YP_034187.1 Full length Holliday junction DNA helicase B Insoluble ++ +
Bartonella henselae YP_033595.1 Full length DNA topoisomerase IV subunit B Insoluble + 
Bartonella henselae YP_033416.1 Full length Hypothetical protein Insoluble ++ 
Borrelia burgdorferi NP_212600.1 Full length Holliday junction DNA helicase B No expression ++ ++
Brucella melitensis YP_419002 Full length Catalase Insoluble ++ +
Brucella melitensis YP_419049 Full length ATP/GTP-binding site motif A (P-loop):ABC transporter:AAA
ATPase:TOBE domain
Insoluble ND ND
Brucella melitensis YP_414617 Full length ATP/GTP-binding site motif A (P-loop):ABC transporter:AAA
ATPase:TOBE domain
No expression ++ ++
Brucella melitensis YP_414349 Full length Acetyl-CoA carboxylase, biotin carboxylase:carbamoyl-phosphate
synthase L chain, ATP-binding:carbamoyl-phosphate synthetase l
No expression ++ +
Brucella melitensis YP_419065 Full length Blue (type 1) copper domain:blue (type 1) copper protein:
amicyanin:plastocyanin
No expression + 
Brucella melitensis YP_419020 Full length Glutamate decarboxylase  Insoluble + 
Brucella melitensis YP_415432 Full length Thioredoxin:thioredoxin type domain:thioredoxin domain 2 Soluble ++ ND
Burkholderia pseudomallei YP_333769 Full length Thioredoxin 1 Soluble ++ ++
Burkholderia pseudomallei YP_334416.1 Full length Chorismate mutase No expression ++ ++
Burkholderia pseudomallei ZP_04891863.1 267–404 Hemagglutinin-family protein Insoluble ++ ++
Burkholderia pseudomallei YP_331616.1 Full length Branched-chain amino-acid ABC transporter, ATP-binding protein Insoluble ++ +++
Burkholderia pseudomallei YP_334791.1 Full length 30S ribosomal protein S9 No expression 
Burkholderia pseudomallei YP_334870 Full length 3-Dehydroquinate dehydratase Insoluble + +++
Burkholderia pseudomallei YP_332852 Full length NADH dehydrogenase subunit I Insoluble + +++
Burkholderia pseudomallei YP_334097 Full length Phosphopyruvate hydratase Insoluble + ND
Burkholderia pseudomallei ABA48070.1 Bp 90–510 Sensor histidine kinase Insoluble ++ ++
Burkholderia pseudomallei YP_333873 Full length ATP-dependent protease ATP-binding subunit No expression + 
Burkholderia pseudomallei YP_334398.2 Full length Adenosine deaminase Soluble +++ ND
Burkholderia pseudomallei YP_334535.1 Full length dTDP-glucose 4,6-dehydratase Soluble ++ ND
Burkholderia pseudomallei YP_333748 Full length Histidyl-tRNA synthetase Soluble 
Ehrlichia ruminantium YP_196632.1 Bp 96–891 FAD-dependent thymidylate synthase ND + ++
Ehrlichia ruminantium YP_196632.1 Bp 96–762 FAD-dependent thymidylate synthase ND + ++
Ehrlichia ruminantium YP_196632.1 Bp 96–654 FAD-dependent thymidylate synthase ND ++ +
Leishmania infantum XP_001464664.1 Full length Elongation factor 1 Insoluble + 
Mycobacterium tuberculosis NP_216165.1 Full length Phenylalanyl-tRNA synthetase subunit  Insoluble +++ +
Mycobacterium tuberculosis NP_216786.1 Bp 57–525 Lipoprotein lppN ND ++ +++
Mycobacterium tuberculosis NP_217463.1 Full length Probable polyketide synthase PKS15 No expression ++ ++
Rickettsia conorii NP_360910.1 Bp 3219–4419 190 kDa cell-surface antigen Insoluble +++ ++
Rickettsia prowazekii AAF34121.1 Bp 1–1095 OmpB Insoluble ++ +
Rickettsia prowazekii NP_221145 Full length NADH dehydrogenase subunit I Insoluble ND ND
Rickettsia rickettsii P15921.1 3900–4953 Outer membrane protein A Insoluble ++ +++
Rickettsia rickettsii YP_001650445.1 Full length Outer membrane protein B ND ++ +
Rickettsia rickettsii AAQ82709.1 3900–4953 Outer membrane protein A ND + +
Trypanosoma brucei XP_822456.1 Full length Hexokinase Insoluble + found in Table 1. Most of the proteins in this set ‘failed’ expression
or solubility testing in E. coli; targets were classiﬁed as ‘failed’ if low
levels of soluble protein were obtained on expression in the standard
E. coli conditions for SSGCID (Myler et al., 2009).
2.2. Cloning
DNA of the target proteins was cloned into the pAVA0421 vector
via ligation-independent cloning (LIC) and grown on LB–carbeni-
cillin plates. The pAVA0421 vector contains an N-terminal hexahis-
tidine afﬁnity tag (MAHHHHHH) for imobilized metal-ion afﬁnity
chromatography (IMAC). Plasmids were puriﬁed using a GenElute
HP Plasmid Mini-Prep Kit (Sigma–Aldrich, Dallas, Texas, USA) and
transformed into E. coli BL21 (DE3) Rosetta cells (EMD Chemicals,
San Diego, California, USA) for expression screening. Small-scale
protein expression was carried out and evaluated by Western blot-
ting. All constructs were sequenced in the forward direction to
conﬁrm that the correct protein target had been cloned.
DNA templates were obtained from the SSGCID pipeline (Myler
et al., 2009). Following E. coli in vivo expression trials, PCR products
of the target gene including the six-His tag were ampliﬁed from the
pAVA0421 vector. The PCR products were then cloned into the cell-
free expression vector pEU-E01-LIC1 (pEU-LIC), which had
previously been modiﬁed to accommodate ligation-independent
cloning. Targets were PCR-ampliﬁed from the prokaryotic expression
vector with RedTaq (Sigma, St Louis, Missouri, USA) using the
primers F, CTCACCACCACCACCACCATATG, and R, ATCC-
TATCTTACTCACTTAGCAGCCGGATCCTCGAG, inserted into
pEU-LIC using ligation-independent cloning and transformed into
Top10 cells (Invitrogen, Carlsbad, California, USA), which were then
grown on LB–carbenicillin plates. Individual colonies were screened
for insertion via colony PCR. DNA from the positive clones was
maxi-prepped (Sigma, St Louis, Missouri, USA) and the full insert
was sequenced in both the forward and reverse directions to conﬁrm
that the correct sequence had been cloned and that the insert was free
of mutations.
2.3. Expression and solubility testing
Transcription reactions for small-scale screening were performed
in PCR strip tubes. In each of the reaction tubes, 2 mg plasmid DNA
was mixed with transcription buffer (80 mM HEPES–KOH pH 7.8
containing 20 mM MgCl2,2m M spermidine hydrochloride, 10 mM
dithiothreitol), 3 mM NTP mix, 2.4 U ml
1 SP6 RNA polymerase and
1.2 U ml
1 RNase inhibitor; RNase-free water was used to bring the
ﬁnal volume to 20 ml. Transcription reactions were then incubated
for 4–6 h at 310 K. A Microcon YM-30 ﬁlter (Millipore, Billerica,
Massachusetts, USA) was used for small-scale mRNA clean-up.
Small-scale translation reactions were performed in 96-well plates
and synthesized RNA was added to the translation mixture; large-
scale reactions were performed using either the Protemist DT II
robot (Cell Free Sciences, Yokohama, Japan), which also performs
sequential transcription, translation and puriﬁcation steps, or the
Protemist XE robot (Cell Free Sciences, Yokohama, Japan), a robot
that performs continuous translation for high yields of protein
production. Small-scale and large-scale translations were performed
using WEPRO1240H (Cell Free Sciences, Yokohama, Japan) cell
extract according to the manufacturer’s instructions. For large-scale
puriﬁcation, the translation mixture was clariﬁed by centrifugation at
6000 rev min
1 for 30 min at 277 K. The supernatant was puriﬁed by
IMAC using a HisTrap FF 5 ml column (GE Biosciences, Piscataway,
New Jersey, USA) equilibrated with binding buffer consisting of
25 mM HEPES pH 7.0, 300 mM NaCl, 5% glycerol, 30 mM imida-
zole, 1 mM tris(2-carboxyethyl)phosphine (TCEP) and eluted with
500 mM imidazole in the same buffer. Concentrated pure protein
was ﬂash-frozen in liquid nitrogen and stored at 193 K. Additional
translations were performed using WEPRO7240H extract (Cell
Free Sciences, Yokohama, Japan) according to the manufacturer’s
instructions. For selected protein targets, NVoy (also known as
NV10), a commercially available linear carbohydrate-based polymer
of 5 kDa molecular weight (Expedeon, San Diego, California, USA),
was used to improve solubility yields. NVoy was added directly to
the translation-reaction mixture in the Protemist XE system at a
concentration of 1 mg ml
1. Solubility was assessed in the presence
and the absence of the NVoy polymer.
From the translation reaction, two 10 ml aliquots were taken. The
total protein from the ﬁrst aliquot was mixed with 10 ml sample
buffer. The other aliquot was spun in a microcentrifuge at top speed
for 60 s; the supernatant (soluble) was separated from the pellet
and mixed with 10 ml sample buffer, while the pellet (insoluble) was
resuspended in 20 ml sample buffer. All samples were boiled at 368 K
for 10 min and 10 ml of each sample was loaded onto a gradient SDS–
PAGE gel (Pierce Bioscience, Rockford, Illinois, USA) for analysis.
Gels were stained with SimplyBlue SafeStain (Invitrogen, Carlsbad,
California, USA) and expression levels were based on visual
inspection of the SDS–PAGE gels and scaling the intensity of the
expected protein bands. The identities of the hexahistidine-tagged
proteins were conﬁrmed by Western blotting using an anti-His anti-
body (Qiagen, Valencia, California, USA). In addition to conﬁrming
that the protein was of the correct size, the protein molecular-weight
standard (Bio-Rad, Hercules, California, USA) was used as a refer-
ence for the quantity of His-tagged protein. Brieﬂy, the approximate
quantity of protein in each marker band was estimated and the band
intensities of the His-tagged proteins were then compared with the
marker proteins. A ‘high’ expression score (+++) corresponded to
greater than 0.75 mg ml
1 target protein in the reaction mixture. A
‘medium’ expression rating (++) corresponded to more than
0.30 mg ml
1 but less than 0.75 mg ml
1 and a ‘low’ expression rating
(+) corresponded to a visible band of less than 0.30 mg ml
1.A
‘no detectable protein’ rating () corresponded to no detectable
expression on either SDS–PAGE or Western blot gels.
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Table 2
Summary of protein-expression level and solubility from the cell-free expression system using small-scale expression, the Protemist DT II and the Protemist XE robotic
platforms.
Conditions included WEPRO1240H and 7240H cell-free extracts in the presence and absence of NVoy. 1240H, WEPRO1240H extract; 7240H, WEPRO7240H extract; (), without
NVoy; (+), with 1 mg ml
1 NVoy.
Small-scale screening Protemist DT II Protemist XE
1240H, () 1240H, (+) 1240H, () 1240H, (+) 7240H, () 7240H, (+) 1240H, () 1240H, (+) 7240H, () 7240H, (+)
No. of targets 44 — 29 5 6 5 4 1 4 2
Any expression (%) 87 — 97 80 67 80 100 100 100 100
Soluble expression (%) 56 — 59 80 17 80 75 100 50 100Ratings of the solubility were also determined by visual inspection
of the protein bands on SafeStained SDS–PAGE gels using a system
similar to that employed for the scoring of expression. The ratio of
the band intensities resulting from the pairs of soluble and insoluble
proteins was used to rate solubility. A high solubility score (+++) was
assigned when 75–100% of the total protein was in the soluble
fraction. A medium solubility rating (++) was assigned when the
soluble and the insoluble fractions were approximately equal in band
intensity. A low solubility rating (+) was assigned when less than 25%
of the total protein intensity was in the soluble fraction. Samples with
an absence of detectable soluble protein were assigned an insoluble
rating ().
3. Results
3.1. Small-scale expression
A total of 44 protein targets were analyzed. Two were from
eukaryotic organisms (Trypanosoma brucei and Leishmania
infantum); the remainder originated in prokaryotes (the genera
Anaplasma, Bartonella, Borrelia, Brucella, Burkholderia, Ehrlichia
and Mycobacterium). In this set, 20% of the protein targets were
soluble when expressed in E. coli, 52% were insoluble and the
remaining 22% were not expressed (Table 1). The ﬁrst stage of the
wheat germ cell-free expression pipeline was designed for small-scale
screening. During these tests, detectable protein was achieved for
87% of targets based on Western blot analysis (Tables 1 and 2). 83%
of the targets expressing insoluble protein in E. coli expressed soluble
protein in the cell-free system (Table 1). These data demonstrate that
the wheat germ cell-free expression system is effective at production
of soluble protein.
3.2. Large-scale expression
A collection of 29 proteins were selected from the ﬁrst set of robust
small-scale-screened targets for further scaling up in the Protemist
DT II using WEPRO1240H extract. (Transcription and translation
reactions as well as afﬁnity puriﬁcation are performed sequentially in
the robot.) From this set, 28 targets produced detectable protein, with
medium to high quantities of protein for 17 of these targets (Table 2).
Additionally, the small-scale expression testing successfully predicted
the expression level and degree of solubility of proteins produced on
the large scale in the DT II robot (data not shown). Of the 29 targets,
ﬁve with varying levels of solubility were selected for testing in the
Protemist XE robot with WEPRO7240H cell-free extract, which has
been optimized for high-level expression of His-tagged proteins using
the Protemist XE (Table 3). Of the ﬁve proteins tested in this system,
large quantities of protein were obtained for four (Table 3, data not
shown), although only small quantities of the protein were soluble.
Small quantities of the ﬁfth protein were produced, but these quan-
tities were sufﬁcient for crystallization using the microcapillary
method (Gerdts et al., 2008; Yadav et al., 2005). As a result, additional
methods were necessary to produce signiﬁcant quantities of soluble
protein.
3.3. Solubility testing
One of the more prominent challenges in the WEPRO7240H
expression system is the tendency of protein products to form
precipitates: some runs of the Protemist XE resulted in a mixture so
turbid that the visible-light sensor was unable to function correctly.
Likewise, large-scale expression using WEPRO1240H with the
Protemist XE resulted in increased protein yields accompanied by a
decrease in solubility (data not shown). One of the advantages of the
in vitro system isthe ability to addreagents asnecessary, such asthose
that help to increase solubility, directly to the translation reaction.
One of the factors contributing to protein aggregation is the inter-
action of exposed hydrophobic patches owing to incorrect protein
folding. We therefore chose to investigate the use of NVoy polymer in
the cell-free system. Nvoy consists of a carbohydrate backbone with
hydrophobic side chains which mask any hydrophobic patches on the
protein, thereby limiting nonspeciﬁc interactions which can cause
aggregation. The effects of the NVoy polymer on solubility and its
impact on expression levels were examined in a series of experiments
carried out in the Protemist DT II on a subset of ﬁve protein targets
(Table 2). This subset consisted of targets for which less than 75%
of the proteins were soluble when expressed in the DT II or XE;
when expressed in E. coli, the protein was predominantly insoluble.
WEPRO1240H in the presence and absence of NVoy was tested for
ﬁve proteins and WEPRO7240H in the presence and absence of
NVoy was tested for ﬁve proteins, four of which were also used in
the WEPRO1240H testing. The NVoy polymer did not decrease the
solubility of any of the proteins tested. For two proteins, the
expression levels were lower in the presence of NVoy, but this
decrease in expression level was accompanied by an increase in
solubility (data not shown, Table 3). One protein, which was com-
pletely insoluble when expressed with WEPRO7240H, was over 75%
soluble when expressed in the same system in the presence of NVoy.
Overall, in seven of the 11 paired NVoy()/NVoy(+) comparisons
the NVoy reagent increased the percentage soluble protein yield and
in half the experiments the reagent more than doubled the yield of
soluble protein; for one protein, we were able to obtain more than
1m gm l
1 soluble protein (Table 3). These tests demonstrate that
NVoy does not substantially reduce total protein yields and in most
tests increased the quantity and the percentage of soluble protein
produced.
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Table 3
Summary of large-scale expression data in the presence or absence of NVoy.
Numbers indicate the numbers of milligrams of soluble protein puriﬁed in a 1 ml reaction cup on the Protemist DT II from each run. (+) and () indicate the presence or absence of
NVoy at a concentration of 1 mg ml
1.
NVoy (+):NVoy () ratio 7240H:1240H ratio
Protein
1240H,
NVoy ()
1240H,
NVoy (+)
7240H,
NVoy ()
7240H,
NVoy (+) 1240H 7240H NVoy () NVoy (+)
Rickettsia conorii NP_360910.1, amino acids 1073–1473 0.37 0.91 0.96 1.72 3 2 3 2
Ehrlichia ruminantium YP_196632.1, amino acids 32–297 0.07 0.15 0.07 0.21 2 3 1 1
Rickettsia prowazekii AAF34121.1, amino acids 1–365 0.21 0.39 0.22 0.48 2 2 1 1
Burkholderia pseudomallei ZP_04891863.1, amino acids 267–404 0.11 0.26 0.13 0.60 2 5 1 2
Leishmania infantum XP_001464664.1 0.24 0.47 0.26 ND 2 ND 1 ND
Trypanosoma brucei XP_822456.1 0.27 0.28 0.28 0.61 1 2 1 24. Discussion
This analysis of expression of proteins from the SSGCID pipeline in
a eukaryotic in vitro system validates the use of the wheat germ cell-
free system for expression of proteins that are either not expressed
or are primarily insoluble when expressed in E. coli. The quantities
of soluble protein were sufﬁcient for microcapillary crystallization as
developed by Emerald BioSystems (Gerdts et al., 2008; Yadav et al.,
2005), although no crystal structures of any of the protein targets in
this set have yet been obtained. Combining the wheat germ cell-free
expression system with a crystallization method such as micro-
capillary crystallization may yield structural data for proteins that
have been difﬁcult to express.
A lingering concern is the tendency for insolubility to increase as
the quantity of protein produced increases. As a result, for most
targets similar quantities of soluble protein were obtained from the
use of WEPRO1240H (optimized for the DT II) and WEPRO7240H
(optimized for high-level expression in Protemist XE) in the absence
of additional solubilizing agents. This may reﬂect the tendency of
the protein to form insoluble aggregates at higher concentrations.
The addition of NVoy substantially increased the quantities of soluble
protein produced, although even in the presence of NVoy the
quantities of soluble protein were insufﬁcient for standard crystal-
lization studies. This demonstrates that NVoy can be added to the
translation reaction to increase solubility, potentially eliminating the
need to denature and refold the protein for solubility. The addition of
other solubilizing reagents may lead to further increases in solubility.
These data demonstrate the utility of the wheat germ cell-free
system for expression of proteins that are insoluble when expressed
in E. coli. The addition of NVoy substantially increased the yield of
soluble protein; this reagent is likely to increase the production of
soluble proteins that are insoluble in E. coli.
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